Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-04-16

Clinical Trial Update: An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy [Phase 2]

View source ↗

Summary

Phase 2 open-label trial of ManNAc in GNE myopathy completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ManNAc (N-acetylmannosamine)

Snippet

Sponsor: National Human Genome Research Institute (NHGRI) | Conditions: GNE Myopathy | Phase 2 | Status: COMPLETED | Results posted: 2019-04-16